BioCatalystWatch
BOLDWorkspace / BOLD / OverviewCompany library
Price
Market cap
Next catalyst—
Cash
Latest company release · Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement ↗

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

History / paused

Kinesin (specific identity not named)

PreINDP1P2P3FilingApproved

CHK1

PreINDP1P2P3FilingApproved

RNR

PreINDP1P2P3FilingApproved

RNR

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

Latest company release · Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement ↗

BOLD PR & News

PR & News

BOLD SEC archive